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Both scarring and nonscarring alopecias have
been described with the long-term use of epidermal
growth factor receptor (EGFR) inhibitors. Current
treatments revolve around anti-inflammatory agents
such as topical corticosteroid ointments, creams,
and intralesional injections to reduce follicular
inflammation. Unfortunately, none of these thera-
pies are universally effective. Here, we describe a
case of erlotinib-induced alopecia refractory to
intralesional and topical corticosteroids that was
successfully treated with doxycycline as a novel
treatment approach for EGFR inhibitoreassociated
alopecia.CASE REPORT
A 77-year-old woman with a 4-year history of
nonesmall cell lung cancer (NSCLC) was started on
the EGFR inhibitor, erlotinib (initial dose of 150 mg
daily), for recurrence of her EGFR-mutated NSCLC
after adjuvant chemotherapy. She experienced a
papulopustular eruption on her face and chest
within 2 weeks after initiating erlotinib therapy,
which resolved after a month of minocycline and
dose reduction of her erlotinib to 100 mg daily. She
otherwise tolerated erlotinib without further derma-
tologic concerns. However, 5 months after initiating
erlotinib, a localized asymptomatic alopecia devel-
oped over her right parietal scalp. Physical exami-
nation revealed a 5- x 3-cm area of alopecia with
peripheral crusting and scale that was clinically
consistent with an erosive pustular form of EGFR
inhibitoreassociated alopecia.
After her diagnosis, the patient received multiple
therapies including intralesional triamcinolone in-
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solution for 1 year, all of which were unsuccessful.
Her alopecia worsened despite treatment and
spread to her left parietal scalp. At the peak of
involvement, she exhibited an 8- x 8-cm area of hair
loss with erythema, yellow crusting, and scale over
her bilateral parietal scalp areas (Fig 1).
Because of her continued scalp inflammation,
lack of improvement on skin-directed corticoste-
roids, and a culture swab that grew Staphylococcus
aureus, the patient was started on 100 mg of oral
doxycycline twice daily with discontinuation of
her other skin therapies. She reported dramatic
improvement of her alopecia with regression of
the lesions, evidence of hair partial regrowth, and
resolution of crusting within 1 to 2 weeks of starting
the medication. Doxycycline was decreased to 50
mg twice a day 6 weeks after initiating treatment.
Physical examination found diminishing areas of
noninflamed scarring alopecia with partial hair
regrowth on the right parietal scalp and no associ-
ated serous drainage or crust (Fig 2).
At her 6-month follow-up visit after initiating
doxycycline, there were no signs of relapse of her
alopecia and no evidence of recurrence of the scalp
crust and drainage. Given the favorable results of her
doxycycline and erlotinib regimen, her doxycycline
was discontinued after a total 6-month treatment
course, and over 3 months after discontinuation the
improvement has been maintained. She was able to
continue her erlotinib at 100 mg throughout withoutJAAD Case Reports 2015;1:289-91.
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Fig 2. Successful treatment of EGFR inhibitoreinduced
alopecia with oral doxycycline. There was significant
improvement of her alopecia 3 months after initiating
oral doxycycline, 100 mg twice daily for 6 weeks followed
by 50 mg twice daily for an additional 4.5 months, with
hair partial regrowth extending to the periphery on the
right parietal and left parietal scalp and resolution of
serous drainage and crusting.
Fig 1. A case of EGFR inhibitoreinduced alopecia in a 77-
year-old woman. Examination of her scalp found bipar-
ietal scalp alopecia with peripheral crusting and scale
despite treatment with topical steroids and bimonthly
intralesional triamcinolone injections.
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outcome of her treatment.DISCUSSION
EGFR overexpression is a common feature of
several different types of cancers, including lung,
pancreas, breast, and colon, and correlates with both
cancer progression and worsening prognosis.1 EGFR
inhibitors are antibodies or small molecules devel-
oped to target EGFR overexpression and slow the
progression of malignancy. Because the EGFR
signaling cascade is also highly involved in the
homeostasis of epidermal keratinocytes and hair
follicles in the skin,2 a variety of cutaneous side
effects from EGFR inhibitor administration has beenreported. The most common of these side effects
include acneiform eruption (85% of patients), xerosis
(35%), paronychia (10%e15%), and mucositis
(rare).3 These cutaneous manifestations are a source
of significant physical and emotional discomfort for
patients.
EGFR signaling is involved in the initiation of the
anagen phase of the hair cycle and acts as an
important regulator of the hair growth phase.
Disruption of this phase with EGFR inhibitors leads
to disorganized formation of the hair follicle and
manifests as abnormalities such as finer, curlier, and
more brittle hair and both scarring and nonscarring
alopecia.3 Alopecia is a late manifestation of EGFR
inhibitoreassociated dermatologic side effects, typi-
cally arising 2 to 3 months after initiation of the
medication, and is characterized by significant inflam-
mation of the scalp with recruitment of lymphocytes,
plasma cells, neutrophils, and eosinophils on histo-
logic examination.4 This inflammation is thought to
arise from inhibition of EGFR from its normal role of
suppressing free radical synthesis, thus resulting in
activation of the inflammatory cascade and leading to
follicle destruction and alopecia.5
Current treatments for EGFR inhibitoreassociated
alopecia center on inflammation modulation with
local anti-inflammatory agents, such as topical hy-
drocortisone, steroid shampoos, and steroid lotions,6
none of which are universally effective. In a review
of 11 cases of EGFR inhibitoreassociated alopecia,
Toda et al4 concluded steroids alone were not an
effective treatment and that reduction or discontin-
uation of the EGFR inhibitor was needed in most
cases to prevent scarring. The clinical practice
guidelines for the prevention and treatment of
EGFR inhibitoreassociated dermatologic toxicities
similarly do not describe any established interven-
tions to reduce or prevent alopecia.5 Current recom-
mended therapies are largely supportive and consist
mainly of approaches to reduce inflammation and
reduction or discontinuation of EGFR inhibitor
therapy as a last resort. Unfortunately, for our
patient, discontinuation of erlotinib was not a favor-
able option given its efficacy against her recurrent
NSCLC.
Doxycycline, as a member of the tetracycline
family, inhibits key proinflammatory mediators such
as nitric oxide and the mitogen-activated protein
kinase pathway.7 These anti-inflammatory effects of
doxycycline may contribute to its success in treating
EGFR inhibitoreassociated alopecia. In addition,
doxycycline is a potent broad-spectrum antibiotic
with good coverage of skin flora. Patients undergoing
EGFR-inhibitor treatment frequently have superin-
fections at sites of toxicity. In one study, 84 of 221
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aureus superinfections after treatment with EGFR
inhibitors.8 S aureus infection has also been linked to
exacerbations of EGFR inhibitoreinduced skin erup-
tions, including that of a papulopustular eruption on
the scalp with associated alopecia.9 Minocycline,
another tetracycline, was reported to help in one
case of folliculitis decalvansetype alopecia associ-
ated with erlotinib10; however, within the tetracycline
family, doxycycline has been linked to fewer severe
toxicities and is safer in patients with renal impair-
ment than minocycline.
The success of doxycycline in treating our pa-
tient’s EGFR inhibitoreassociated alopecia may be a
combination of its potent anti-inflammatory and
antibiotic properties. Although further studies are
required, doxycycline should be considered a po-
tential therapeutic option for corticosteroid-resistant
EGFR inhibitoreinduced alopecia.
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